Vanda Pharmaceuticals (NASDAQ:VNDA) enrolled the first patient in its Phase 3 trial assessing tradipitant for the treatment of neurogenic inflammation of the lung, secondary to COVID-19 infection.
The study will enroll some 300 patients with confirmed COVID-19 pneumonia who will receive either tradipitant, a neurokinin-1 receptor antagonist, or placebo.
“Our primary focus is to quickly evaluate the impact of tradipitant in the treatment of patients with neurogenic inflammation of the lung as a result of COVID-19,” Dr. Bushra Mina, lead study investigator and section chief of pulmonary medicine, director of pulmonary & critical care fellowship at Lenox Hill Hospital, said in a statement.
“The initiation of this clinical trial represents a significant milestone in our efforts to combat this health crisis and support our ultimate goal of patient recovery,” he added.
The trial is being conducted at New York City’s Lenox Hill Hospital in collaboration with The Feinstein Institutes for Medical Research.
